Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... CAMBRIDGE, Mass. , May 5, 2015 /PRNewswire/ ... the closing of its initial public offering of ... offering price of $18.00 per share, including shares ... by the underwriters of their option to purchase ... public offering to Blueprint Medicines were approximately $168.6 million, ...
(Date:5/5/2015)... May 05, 2015 Hayden-McNeil ... to develop custom course materials for smaller courses. This ... as low as 200 students. , “I’m very ... range of higher education instructors,” said Jeff McCarthy, Hayden-McNeil ... we can do our part to make education both ...
(Date:5/5/2015)... 2015  Renova™ Therapeutics, a biopharmaceutical company developing ... other chronic diseases, has engaged RAND Health Advisory ... reflect the healthcare patterns of multiple advanced heart ... used to characterize the impact the company,s lead ... groups of patients and the overall health care ...
(Date:5/5/2015)... May 05, 2015 Franz Inc ., ... today announced that its flagship product, AllegroGraph, has been named ... Database Market Update report. AllegroGraph is a high ... W3C industry standards. Graph databases are skyrocketing in popularity and ... to a recent DBMS ranking by DB-Engines. , ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... ... More Economical Genetic Testing to Facilitate Breed Improvements. Producers, breed associations, livestock researchers ... device that will positively impact the industry’s ability to accelerate breed improvements and ... ...
... ... research databases. , ... January 8, 2010 -- The Society for Clinical Data Management recently published Edit Check Design ... tool for efficiency and data quality., , ,The chapter is a new addition to SCDM’s ...
... Fast-Growing ... partner. , ... Triangle Park, NC (PRWEB) -- TechCFO , one of Inc. Magazine’s 500 Fastest ... and biotechnology companies, today announced the expansion of its Research Triangle Part office with ...
Cached Biology Technology:DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 2DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 3DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 4SCDM Releases Best Practices for Automated Data Cleaning 2TechCFO Continues Research Triangle Park Expansion; Garrison Named New Partner 2
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... study of a space-age, low-gravity training machine used by ... muscles and joints by nearly half when subjects ran ... weight. The new study has implications for both ... returning from knee and hip surgeries, according to Associate ...
... imported foods in the food supply continues to increase, Americans ... disease as some countries may not have the same sanitary ... and Challenges , the latest book in the ASM ... of the greatest weaknesses in the U.S. food safety system ...
... resistance on the rise, tuberculosis is emerging as a bigger ... innovative research at Weill Cornell Medical College suggests that ... one that could be a prime target for drug development. ... protein that,s essential to the defense that M. tuberculosis ...
Cached Biology News:Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 2Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 3New publication addresses safety of imported foods 2Potential new drug target to fight tuberculosis identified 2Potential new drug target to fight tuberculosis identified 3
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... GenePaint system, which is based on a new ... for performing in situ hybridization of tissues on ... in the study of gene expression, in situ ... tissues and can be used to validate and ...
... scanning and positioning system is designed ... to be positioned or scanned with ... provides superior responsiveness compared to micropositioners ... (X or XY stage) are driven ...
... Array Analyst Software has been optimized for ... algorithms allow the software to quickly and ... each well of an ELISA plate or ... Analyst Software has been customized to incorporate ...
Biology Products: